Skip to main content

Parasympathomimetics — Legacy and Specialty Uses

Parasympathomimetics in urology (the direct muscarinic agonist bethanechol and the cholinesterase inhibitors neostigmine, pyridostigmine, and distigmine) are the classic pharmacologic approach to detrusor underactivity (DUA), nonobstructive urinary retention, and neurogenic bladder. The evidence remains limited: Moro’s 2022 systematic review found low-quality data with short follow-up and could not draw clear evidence-based conclusions, while a 2007 review concluded that available studies did not support parasympathomimetics for underactive bladder.[1][2][3] They remain in the legacy category because no better pharmacologic alternative exists; modern urology still has no approved therapy that reliably augments detrusor voiding contraction strength.[3][23] EAU Neuro-Urology 2026 strongly recommends against prescribing parasympathomimetics for underactive detrusor. The 2026 EAU female and male LUTS guidelines both strongly recommend against routine use for underactive bladder; intermittent catheterization provides drainage when emptying is inadequate.[24][25][26]

For the standard framework (muscarinic-receptor physiology, bethanechol dosing per FDA label, contraindications, and the role of CIC), see the Cholinergic agonists hub.

Classification — Direct vs Indirect​

ClassAgentsMechanism
Direct muscarinic agonistsBethanechol (FDA-approved for urology)Quaternary amine; directly stimulates M₃ detrusor receptors; resistant to cholinesterase hydrolysis; does not cross the BBB[4]
Indirect — reversible AChE inhibitorsNeostigmine, pyridostigmineInhibit ACh hydrolysis → ↑ synaptic ACh at parasympathetic terminals; require intact parasympathetic innervation to work[5][15][17]
Indirect — long-acting AChE inhibitorDistigmine (Japan)Bis-carbamate with strong bladder-AChE binding; sustained effects in animal experiments[6][7][8][22]

In guinea pigs, distigmine increased maximum intravesical pressure for at least 12 hours after a single intravenous dose despite falling plasma levels.[22] In isolated guinea-pig detrusor, potentiation persisted for 12 hours after washout, compared with up to 3 hours for neostigmine or pyridostigmine.[8]

Bethanechol — Historical Diagnostic Roles​

Bethanechol's role as a diagnostic probe of the bladder predates its role as a therapeutic, and much of the legacy literature is diagnostic rather than therapeutic.

The Bethanechol Supersensitivity Test (BST)​

The BST was introduced to distinguish neuropathic from non-neuropathic detrusor areflexia using Cannon's law of denervation supersensitivity: a denervated muscle responds disproportionately to its agonist. The test protocol:

  • Subcutaneous bethanechol, 5 mg in the Wheeler series, during cystometry[13]
  • EAU 2026 describes a positive bethanechol test as a detrusor contraction > 25 cm H₂O, historically thought to indicate denervation supersensitivity[24]

The historical evidence:

StudynFindings
Pavlakis 19836398% sensitivity, 100% specificity for neuropathic areflexia[11]
Sidi 19885790% sensitivity, 95.6% specificity; combined with rhabdosphincter EMG and bulbocavernosus reflex latency → accuracy ~ 100%[10]
Blaivas 19803324% false-negative rate, 50% false-positive rate — "insufficient for diagnosis alone"[12]
Wheeler 19887Documented borderline or positive BST (19–55 cm H₂O after 5 mg SC) in neurologically normal women — further eroded its specificity[13]

EAU Neuro-Urology 2026 states there is currently no indication for the test, noting equivocal results in practice.[24] It is now largely of historical interest. The historical BST used subcutaneous bethanechol, whereas the later intravesical electromotive approach delivered it through an electrode catheter.[13][14]

Electromotive intravesical bethanechol​

In the Riedl study, intravesical bethanechol 20 mg in 150 mL of 0.3% sodium chloride was delivered with 20 mA pulsed current through an electrode catheter.[14] In the Riedl 2000 series of 45 patients with detrusor areflexia:[14]

  • 24 / 26 patients with neurologic disease showed mean pressure increase of 34 cm H₂O[14]
  • Among patients with chronic bladder distension, 3 / 11 had a mean pressure rise of only 3 cm H₂O[14]
  • Oral bethanechol (25 mg once daily, 6 weeks) restored spontaneous voiding in 9 / 11 electromotive-positive patients treated, and in 0 / 4 without a pressure rise[14]

Riedl and colleagues proposed electromotive testing to identify patients who might respond to oral bethanechol.[14] EAU 2026 notes no follow-up was published.[24]

Bethanechol — Therapeutic Evidence Today​

The aggregate picture is weak.[1][2]

SourceFindings
Moro 2022 SR/meta (12 trials, n = 3,024)Statistically significant reduction in patients with urinary retention (RR 0.55, 95% CI 0.3–0.98; low-quality evidence); PVR reduction at ≤ 1 week (MD −77.5 mL) but no difference at 1 month or in overall postvoid volume; no difference in adverse events (moderate-quality evidence); authors concluded overall evidence insufficient for firm evidence-based conclusions[1]
Barendrecht 2007 SR (10 RCTs)3 positive / 6 negative / 1 harmful; "evidence does not support use"[2]
Buckley-Lapitan Cochrane (POUR; 7 studies, n = 494)Cholinergic agents alone showed no significant association with successful treatment; cholinergic + sedative combination was associated with spontaneous voiding (RR 1.39; 95% CI 1.07–1.82) but with significant heterogeneity between the two studies[5]
EAU Neuro-Urology 2026; EAU Female LUTS 2026"Do not prescribe parasympathomimetics for underactive detrusor" ; "Do not routinely recommend parasympathomimetics for treatment of women with UAB" ; oral parasympathomimetics do not improve clinical or urodynamic parameters (LE 1b)[24][25]
Gaitonde NAMCS 2003–2013Among women's visits for LUTS, neurogenic bladder or retention, bethanechol was prescribed at 0.8% — 92% of prescribing visits were with urologists, 79% were continued medications; mean age 62.3, for detrusor atony (35%), retention (20%), neurogenic bladder (18%)[9]

Despite weak evidence and the lack of an approved detrusor-strengthening drug, bethanechol remains in use.[3][9]

Critical safety concern: if the external sphincter fails to relax while bethanechol contracts the bladder, urine can be forced retrograde up the ureter, causing vesicoureteral reflux and, in the setting of bacteriuria, ascending pyelonephritis.[4] Exclude bladder outlet obstruction and confirm reasonable sphincter coordination before initiating. For the full framework, see the Cholinergic agonists hub.

Bethanechol label essentials (US)​

ItemLabel content[4]
IndicationAcute postoperative and postpartum nonobstructive (functional) urinary retention; neurogenic atony of the bladder with retention
DoseUsual adult oral dose 10–50 mg three or four times daily, individualized. Titration: 5–10 mg, repeated at hourly intervals until response or a cumulative 50 mg. Take on an empty stomach (1 h before or 2 h after meals) to limit nausea and vomiting
Time courseOnset sometimes within 30 min, usually maximal at 60–90 min; duration about 1 h at usual doses
ContraindicationsHyperthyroidism, peptic ulcer, latent or active bronchial asthma, pronounced bradycardia or hypotension, vasomotor instability, coronary artery disease, epilepsy, parkinsonism; mechanical obstruction, possible gastrointestinal obstruction, and bladder neck obstruction; questionable GI or bladder wall strength or integrity; recent bladder surgery or GI resection and anastomosis; peritonitis, acute GI inflammation, spastic gastrointestinal disturbances, marked vagotonia; hypersensitivity
Adverse effectsRare orally, more frequent with dose increases: abdominal cramps, nausea, belching, diarrhea, salivation, urinary urgency, headache, malaise, flushing and sweating, hypotension with reflex tachycardia, bronchoconstriction, lacrimation, miosis
InteractionGanglion-blocking drugs: a critical fall in blood pressure may occur (abdominal symptoms usually precede it)
OverdoseAtropine is the specific antidote (label adult dose 0.6 mg, repeated every 2 h according to response); subcutaneous injection is preferred except in emergencies, when intravenous administration may be used

Neostigmine — Specialty Perioperative Use​

Neostigmine's urologic footprint is limited to one clinical niche and one preclinical signal.

Time to first void after spinal anesthesia​

Senapathi 2018 RCT (n = 36 post-spinal-anesthesia patients, IM neostigmine 0.5 mg versus placebo):[15]

  • Median time to first voiding 40 min (range 20–70) on neostigmine versus 75 min (55–135) control (p ≤ 0.05)
  • Time to first voiding after the spinal block 280.8 versus 364.2 min (p ≤ 0.05)

In this 36-patient trial, neostigmine shortened time to first void but did not significantly reduce postoperative urinary retention or catheterization (1/18 versus 3/18 catheterized).[15] Pelvic, urologic, and anorectal operations were excluded, limiting direct application to reconstructive practice.[15] Neostigmine also has cholinergic adverse effects, including bradycardia, bronchospasm, and gastrointestinal cramping.[28]

Diabetic bladder dysfunction — preclinical​

In a rat model of diabetic cystopathy, neostigmine potentiated electrical-field-stimulation–induced bladder contractions more in diabetic strips than in controls, suggesting that elevated bladder cholinesterase activity may contribute to DUA in late-stage diabetic bladder, and that AChE inhibition could become a therapeutic target in this specific population.[16] This has not translated into human trials.

Pyridostigmine — The Emerging Agent​

Two small 2025 randomized trials reported favorable outcomes. EAU 2026 recommends against prescribing parasympathomimetics for underactive detrusor.[24][25]

Post-TURP underactive bladder​

Zeinelabden 2025 double-blind RCT (men with BPH and preoperative UAB randomized after TURP; 73 randomized, 66 analyzed [34 pyridostigmine, 32 placebo]; pyridostigmine 120 mg/day for 3 months versus placebo):[18]

  • Significant improvement in IPSS (p = 0.001)
  • Significant QoL improvement (p < 0.05)
  • At three months, Qmax, PVR and calculated bladder contractility index favored pyridostigmine, but detrusor pressure at maximum flow did not differ between arms (50.26 versus 47.47 cm H₂O; p = 0.397).[18]

The single-center study followed patients for only three months, excluded diabetes or neurological disease and selected surgical complications, and reported adverse effects in 8/34 treated patients (23.5%), including one severe diarrhea episode that led to discontinuation.[18] Durability and broader applicability remain uncertain.

Acute urinary retention due to BPH​

Mohamed 2025 RCT (n = 140, first-episode AUR due to BPH, pyridostigmine 60 mg three times daily plus silodosin 8 mg daily for one week before TWOC versus silodosin alone):[19]

  • Successful trial without catheter (TWOC): 82.9% versus 67.1% (combination superior)[19]
  • Among patients who passed the day-7 TWOC (58/70 versus 47/70), IPSS did not differ at 2 weeks (18 versus 18; p = 0.861) but favored combination treatment at 3 months (11 versus 13; p < 0.001). Qmax favored combination at 2 weeks (13 versus 12 mL/s; p = 0.003) and 3 months (15 versus 14 mL/s; p < 0.001).[19]

Mechanical urinary obstruction is a labeled contraindication.

Autonomic failure with combined orthostasis and bladder dysfunction​

  • Yamamoto 2006 case report (66-year-old man with autonomic failure): pyridostigmine 180 mg/day improved both orthostatic hypotension and underactive detrusor bladder dysfunction[20]
  • Increased gut motility and urinary urgency may help selected patients with autonomic failure, constipation, or impaired bladder emptying, but these effects can also be adverse.[20][21]

Pyridostigmine is contraindicated in mechanical intestinal or urinary obstruction, and the label advises particular caution in bronchial asthma; its US labeling is for myasthenia gravis, so these urologic uses are off-label. Exclude obstruction before adding it to an α-blocker in any BPH scenario. Pyridostigmine is mainly excreted unchanged by the kidney; renal disease may require a lower dose titrated to effect.[17]

Distigmine — The Japanese Option​

Distigmine (used in Japan for detrusor underactivity and myasthenia gravis) is pharmacologically distinct from other AChE inhibitors:

  • In guinea pigs, 0.1 mg/kg IV increased maximum intravesical pressure for ≥12 h despite falling plasma levels.[22]
  • Compared head-to-head with neostigmine, pyridostigmine, and ambenonium in guinea-pig detrusor, distigmine's potentiating effect was significantly more sustained (> 12 h versus approximately 3 h)[8]
  • Mechanistically, distigmine selectively potentiates the cholinergic component of parasympathetic nerve–induced bladder contraction without affecting the purinergic (ATP-mediated) component[6][7]

Distigmine is not a US urologic therapy; availability and labeling differ internationally. Japanese regulatory safety information reports fatal distigmine-associated cholinergic crises, many within the first two weeks; renal impairment can increase drug exposure.[27]

Evidence Summary​

AgentClassUrologic FDA statusLabeled indication or studied contextEvidence quality
BethanecholDirect muscarinic agonistFDA-approved — acute postoperative / postpartum nonobstructive retention; neurogenic bladder atony with retention[4]Labeled retention indications; historical DUA use, although EAU recommends against routine parasympathomimetics for women with non-neurogenic UAB [25] and against prescribing them for neurogenic underactive detrusor [24]Low — Moro 2022 meta signal[1]; Barendrecht 2007 SR negative[2]
NeostigmineReversible AChE inhibitorNone urologicEarlier first void after spinal anesthesia in non-urologic surgery; preclinical diabetic bladderVery low — Senapathi n = 36 RCT[15]
PyridostigmineReversible AChE inhibitorNone urologicPost-TURP UAB; add-on for BPH AUR (with α-blocker); autonomic failureSmall studies; uncertain generalizability — two 2025 RCTs[18][19]
DistigmineLong-acting AChE inhibitorApproved in Japan for DUARegional use; verify local authorizationPreclinical mechanistic strong[6][7][8][22]; clinical data regional

Practical Pearls​

  • Exclude mechanical urinary obstruction before prescribing bethanechol or pyridostigmine. The bethanechol label warns that contraction against a nonrelaxing sphincter can force urine retrograde and cause reflux infection when bacteriuria is present; the pyridostigmine label contraindicates mechanical urinary obstruction.[4][17]
  • Intermittent catheterization provides bladder drainage when emptying is inadequate.[3] EAU 2026 strongly recommends it as a standard treatment for women unable to empty; the neuro-urology guideline describes it as historically preferred for neurological patients unable to empty effectively.[24][25]
  • Cholinergic crisis requires urgent resuscitation and toxicology input. Atropine antagonizes muscarinic effects; when used to suppress pyridostigmine adverse effects, it can mask signs of overdosage and delay recognition of cholinergic crisis.[17] The bethanechol-label schedule is specific to bethanechol poisoning.[4]
  • The Bethanechol Supersensitivity Test is of historical interest only. Quote Pavlakis and Sidi if asked; quote Blaivas and Wheeler to explain why it is no longer used.[10][11][12][13]
  • Electromotive bethanechol testing remains investigational or historical, without broad validation for routine selection.[14]
  • Pyridostigmine plus α-blocker is worth knowing about for first-episode BPH AUR. Mohamed 2025 reported day-7 TWOC success in 58/70 (82.9%) versus 47/70 (67.1%) after one week of treatment.[19] Must not override mechanical-obstruction contraindications.[17]
  • Pyridostigmine in autonomic failure is the rare case where the side-effect profile (↑ GI motility, urinary urgency) is therapeutically desired.[20][21]
  • Distigmine does not exist in the US pharmacopeia.[8][22]
  • The DUA pharmacologic pipeline is active. Acotiamide, ASP8302, neurokinin-2 agonists, TRPV-4 modulators are all under investigation.[23] None of these investigational mechanisms should displace established emptying and upper-tract protection strategies.

See Also​

References​

1. Moro C, Phelps C, Veer V, et al. "The effectiveness of parasympathomimetics for treating underactive bladder: a systematic review and meta-analysis." Neurourol Urodyn. 2022;41(1):127–139. doi:10.1002/nau.24839

2. Barendrecht MM, Oelke M, Laguna MP, Michel MC. "Is the use of parasympathomimetics for treating an underactive urinary bladder evidence-based?" BJU Int. 2007;99(4):749–752. doi:10.1111/j.1464-410X.2006.06742.x

3. Drake MJ, Williams J, Bijos DA. "Voiding dysfunction due to detrusor underactivity: an overview." Nat Rev Urol. 2014;11(8):454–464. doi:10.1038/nrurol.2014.156

4. Bethanechol chloride tablets: US prescribing information. DailyMed label. Updated January 29, 2026.

5. Buckley BS, Lapitan MC. "Drugs for treatment of urinary retention after surgery in adults." Cochrane Database Syst Rev. 2010;(10):CD008023. doi:10.1002/14651858.CD008023.pub2

6. Obara K, Kobayashi Y, Chino D, Tanaka Y. "Effect of distigmine on the contractile response of guinea pig urinary bladder to electrical field stimulation." Eur J Pharmacol. 2017;809:209–214. doi:10.1016/j.ejphar.2017.05.031

7. Obara K, Kobayashi Y, Chino D, Tanaka Y. "Effects of distigmine on electrical field stimulation-induced contraction of mouse urinary bladder smooth muscles." Pharmacology. 2017;99(3-4):106–113. doi:10.1159/000452222

8. Obara K, Ogawa T, Chino D, Tanaka Y. "The long-lasting enhancing effect of distigmine on acetylcholine-induced contraction of guinea pig detrusor smooth muscle correlates with its anticholinesterase activity." Biol Pharm Bull. 2017;40(7):1092–1100. doi:10.1248/bpb.b17-00175

9. Gaitonde S, Malik RD, Christie AL, Zimmern PE. "Bethanechol: is it still being prescribed for bladder dysfunction in women?" Int J Clin Pract. 2019;73(8):e13248. doi:10.1111/ijcp.13248

10. Sidi AA, Dykstra DD, Peng W. "Bethanechol supersensitivity test, rhabdosphincter electromyography and bulbocavernosus reflex latency in the diagnosis of neuropathic detrusor areflexia." J Urol. 1988;140(2):335–337. doi:10.1016/s0022-5347(17)41596-5

11. Pavlakis AJ, Siroky MB, Krane RJ. "Neurogenic detrusor areflexia: correlation of perineal electromyography and bethanechol chloride supersensitivity testing." J Urol. 1983;129(6):1182–1184. doi:10.1016/s0022-5347(17)52629-4

12. Blaivas JG, Labib KB, Michalik SJ, Zayed AA. "Failure of bethanechol denervation supersensitivity as a diagnostic aid." J Urol. 1980;123(2):199–201. doi:10.1016/s0022-5347(17)55853-x

13. Wheeler JS, Culkin DJ, Canning JR. "Positive bethanechol supersensitivity test in neurologically normal patients." Urology. 1988;31(1):86–89. doi:10.1016/0090-4295(88)90584-5

14. Riedl CR, Stephen RL, Daha LK, et al. "Electromotive administration of intravesical bethanechol and the clinical impact on acontractile detrusor management: introduction of a new test." J Urol. 2000;164(6):2108–2111. doi:10.1016/s0022-5347(05)66979-0

15. Senapathi TGA, Wiryana M, Subagiartha IM, et al. "Effectiveness of intramuscular neostigmine to accelerate bladder emptying after spinal anesthesia." Ther Clin Risk Manag. 2018;14:1685–1689. doi:10.2147/TCRM.S176281

16. Mustafa S, Ismael HN. "Reactivity of diabetic urinary bladder to the cholinesterase inhibitor neostigmine." Urology. 2014;84(6):1549.e1–5. doi:10.1016/j.urology.2014.08.019

17. Pyridostigmine bromide tablets: US prescribing information. DailyMed label. Accessed September 12, 2026.

18. Zeinelabden KM, El-Shazly M, Alorabi A, et al. "The efficacy of pyridostigmine therapy after transurethral resection of prostate in cases with underactive urinary bladder: prospective randomized trial." World J Urol. 2025;43(1):473. doi:10.1007/s00345-025-05842-8

19. Mohamed AG, Badawy HF, Said ASA, et al. "Additive value of pyridostigmine to silodosin in the management of acute urinary retention secondary to benign prostatic hyperplasia: a randomized controlled trial." J Clin Med. 2025;14(3):674. doi:10.3390/jcm14030674

20. Yamamoto T, Sakakibara R, Yamanaka Y, et al. "Pyridostigmine in autonomic failure: can we treat postural hypotension and bladder dysfunction with one drug?" Clin Auton Res. 2006;16(4):296–298. doi:10.1007/s10286-006-0358-z

21. Freeman R, Abuzinadah AR, Gibbons C, et al. "Orthostatic hypotension: JACC state-of-the-art review." J Am Coll Cardiol. 2018;72(11):1294–1309. doi:10.1016/j.jacc.2018.05.079

22. Obara K, Chino D, Tanaka Y. "Distigmine bromide produces sustained potentiation of guinea-pig urinary bladder motility by inhibiting cholinesterase activity." Biol Pharm Bull. 2017;40(6):807–814. doi:10.1248/bpb.b16-00901

23. Sinha S, Cruz F, Cuenca EM, et al. "Is it possible to regenerate the underactive detrusor? Part 1. Molecular and stem cell therapies targeting the urinary bladder and neural axis — ICI-RS 2024." Neurourol Urodyn. 2025;44(3):577–584. doi:10.1002/nau.25597

24. EAU Guidelines on Neuro-Urology, limited update March 2026: sections 3.3.7 (bethanechol test), 3.4.2.c.2 and 3.4.2.d (drugs for voiding symptoms; recommendations). uroweb.org.

25. EAU Guidelines on Management of Non-neurogenic Female LUTS, limited update March 2026: section 4.4.4.b.1 (parasympathomimetics) and recommendations. uroweb.org.

26. European Association of Urology. EAU Guidelines on the Management of Non-neurogenic Male Lower Urinary Tract Symptoms (LUTS). 2026 ed., section 5.7.4.a (parasympathomimetics) and recommendations. Guideline.

27. Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare. Pharmaceuticals and Medical Devices Safety Information. No. 267 (March 2010):17–19, Revision of PRECAUTIONS (No. 214), distigmine bromoide preparation. PMDA bulletin.

28. Dr. Reddy’s Laboratories Inc. Neostigmine Methylsulfate Injection, USP: US Prescribing Information. Revised February 2024. DailyMed label.